Company
Redbiotec AG
Incorporated
November 2006
Headquarter
Schlieren
Support
Therapeutic bacteria for treating cancer & genetic disorders
Redbiotec develops therapeutic bacteria to treat cancer and genetic disorders. Designed to overcome delivery hurdles faced by other vehicles, the proprietary bacteria platform accommodates large and diverse therapeutic cargos ranging from oncolytic virus to gene editing system. The company builds upon its teams expertise in microbial engineering and immunology. During its era as a vaccine innovator, Redbiotec has sold its CMV vaccine business to Pfizer in 2015 and also created an HSV-2 immunotherapy.
